The company had said in patents that they own the composition of matter. What's that?
Patenting a Composition of Matter
http://inventingpatents.com/composition-matter-claims/
Notice when Anavex announced their patent last week it was for Composition of Matter
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX™ 2-73
September 5, 2017
http://www.anavex.com/anavex-life-sciences-is...avex-2-73/
Herantis didn't do Composition of Matter maybe because it's already take
Herantis Pharma granted a U.S. patent on therapeutic use of MANF
23 May 2017 at 9:00 am
http://herantis.com/release/herantis-pharma-g...e-of-manf/
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
MAY 05, 2015
http://www.otcmarkets.com/stock/AMBS/news?id=103671
Amarantus BioSciences Wins MANF Patent Challenge in Europe
NOVEMBER 20, 2012
http://www.amarantus.com/news/press-releases/...-in-europe
Amarantus BioSciences Awarded US Patent Protecting Composition Of Matter For MANF
Jan 11, 2012 9:42 AM EST
https://www.thestreet.com/story/11373044/2/am...-manf.html
Transcript of Amarantus BioScience
Quarterly Update November 18, 2013
http://content.stockpr.com/amarantus/media/78...1a9e42.pdf
The bottom line is there will hopefully be many therapeutic patents in many manf indications, As GC has said, they all have to come though Amarantus to do a deal. Thus is why there are already some outstanding agreements out there, The research companies need Amarantus and Amarantus need them, Amarantus is a holding company and not a big research lab
Patenting a Composition of Matter
Quote:Composition of matter claims are considered to be among the most powerful patent claims possible because they are broadly applicable . They cover any use of the claimed composition of matter. (By contrast method claims would only cover one method but not necessarily other uses).
http://inventingpatents.com/composition-matter-claims/
Notice when Anavex announced their patent last week it was for Composition of Matter
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX™ 2-73
September 5, 2017
http://www.anavex.com/anavex-life-sciences-is...avex-2-73/
Herantis didn't do Composition of Matter maybe because it's already take
Herantis Pharma granted a U.S. patent on therapeutic use of MANF
23 May 2017 at 9:00 am
http://herantis.com/release/herantis-pharma-g...e-of-manf/
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
MAY 05, 2015
Quote:"We will continue to strengthen our robust intellectual property estate to further protect and maintain our proprietary rights, which we believe will not only allow us to capitalize on the known opportunities for MANF development, but will also further entrench Amarantus as the leading company for new collaborations in light of emerging potential MANF applications ."
http://www.otcmarkets.com/stock/AMBS/news?id=103671
Amarantus BioSciences Wins MANF Patent Challenge in Europe
NOVEMBER 20, 2012
Quote:"This is a highly significant decision for Amarantus, after an extended period of uncertainty," said Marc Wilkinson PhD, European Patent Attorney of UK firm Avidity IP, representing Amarantus. "The Opposition Division's decision validates broad protection for MANF and derivatives across major European jurisdictions."
http://www.amarantus.com/news/press-releases/...-in-europe
Amarantus BioSciences Awarded US Patent Protecting Composition Of Matter For MANF
Jan 11, 2012 9:42 AM EST
Quote:The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF".
https://www.thestreet.com/story/11373044/2/am...-manf.html
Transcript of Amarantus BioScience
Quarterly Update November 18, 2013
Quote:Participants
Gerald Commissiong – President & CEO
Dr. David Lowe, PhD – Independent Director
Dr. Adam Simon – Corporate Advisor
Analysts
Jason Napodano – Zacks
John Petrosino – JWP Incorporated
.Quote:One of the things that we’re very focused on, obviously, is aggregating the patent landscape for MANF. One of the important things that Dr. Lowe mentioned is that we do have avery strong patent position. We own Composition of Matter Patent, as well as certain method of use patents for MANF in the areas of neurology, and that can cover a very significant area. In the case of intellectual property, you think both of enabling IP and freedom to operate, so we want to be in a position where all MANF roads come through Amarantus , and we feel as though we’re in a very strong position to do that now with the balance sheet we have on the table.
Concurrently with that, we have a number of investigators throughout the world on the MANF side, who are starting to use MANF in various indications, so these
investigators are currently producing data that the company is aware of. The
company has entered into material transfer agreements with a number of these investigators, both in indications that are known to the public, such as retinitis, as well as in other indications, which may not be known to the public, in orphan areas, as well as in other areas. We are aggressively pursuing that pathway. We do expect data to be coming out on MANF in various programs over the next six months
http://content.stockpr.com/amarantus/media/78...1a9e42.pdf
The bottom line is there will hopefully be many therapeutic patents in many manf indications, As GC has said, they all have to come though Amarantus to do a deal. Thus is why there are already some outstanding agreements out there, The research companies need Amarantus and Amarantus need them, Amarantus is a holding company and not a big research lab
8
